NEUPRO Drug Patent Profile

Which patents cover Neupro, and what generic alternatives are available?

Neupro is a drug marketed by Ucb Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in thirty countries.

The generic ingredient in NEUPRO is rotigotine. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rotigotine profile page.

DrugPatentWatch^® Generic Entry Outlook for Neupro

Neupro was eligible for patent challenges on May 9, 2011.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 1, 2032. This may change due to patent challenges or generic licensing.

There have been twelve patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NEUPRO

International Patents:	72
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	41
Patent Applications:	1,654
Drug Prices:	Drug price information for NEUPRO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEUPRO
What excipients (inactive ingredients) are in NEUPRO?	NEUPRO excipients list
DailyMed Link:	NEUPRO at DailyMed

See drug prices for NEUPRO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NEUPRO

Constraining patent/regulatory exclusivity:

6,884,434

NDA:

021829

Dosage:

FILM, EXTENDED RELEASE;TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NEUPRO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eva Pharma	NA
MARC-CRO	NA
Virginia Commonwealth University	Phase 2

See all NEUPRO clinical trials

Pharmacology for NEUPRO

Drug Class	Nonergot Dopamine Agonist
Mechanism of Action	Dopamine Agonists

Paragraph IV (Patent) Challenges for NEUPRO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEUPRO	Extended-release Transdermal Film	rotigotine	1 mg/24 hr 2 mg/24 hr 3 mg/24 hr 4 mg/24 hr 6 mg/24 hr 8 mg/24 hr	021829	1	2013-11-26

US Patents and Regulatory Information for NEUPRO

NEUPRO is protected by five US patents.

This potential generic entry date is based on patent 6,884,434.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-006	Apr 2, 2012		RX	Yes	No	9,925,150		Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-006	Apr 2, 2012		RX	Yes	No	10,130,589		Y
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-004	Apr 2, 2012		RX	Yes	No	8,246,979		Y

Expired US Patents for NEUPRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-005	Apr 2, 2012	7,413,747
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-006	Apr 2, 2012	6,699,498
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-004	Apr 2, 2012	6,699,498

EU/EMA Drug Approvals for NEUPRO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
UCB Pharma S.A.	Leganto	rotigotine	EMEA/H/C/002380Leganto is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.Leganto is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ‘on-off’ fluctuations).	Withdrawn	no	no	no	2011-06-16
UCB Pharma S.A.	Neupro	rotigotine	EMEA/H/C/000626Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.	Authorised	no	no	no	2006-02-15

International Patents for NEUPRO

See the table below for patents covering NEUPRO around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	334187
Mexico	2012007326	POLIVINILPIRROLIDONA PARA LA ESTABILIZACION DE UNA DISPERSION SOLIDA DE FORMA NO CRISTALINA DE ROTIGOTINA. (POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE.)
Serbia	65853	POLIVINILPIROLIDON ZA STABILIZACIJU ČVRSTE DISPERZIJE NEKRISTALNOG OBLIKA ROTIGOTINA (POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE)

Supplementary Protection Certificates for NEUPRO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1033978	24/2006	Austria		PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 - EU/1/05/331/013 20060215
1033978	CA 2006 00020	Denmark		PRODUCT NAME: ROTIGOTINE
1033978	SZ 24/2006	Austria		PRODUCT NAME: ROTIGOTINE

NEUPRO (Rotigotine) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

NEUPRO (rotigotine) is a transdermal dopamine agonist approved for the treatment of Parkinson's disease (PD) and moderate-to-severe primary restless legs syndrome (RLS). The drug's market performance is shaped by patent exclusivities, regulatory approvals, competition, and clinical utility.

What is the Approved Indication for NEUPRO?

NEUPRO is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease [1]. It is also approved for the treatment of moderate-to-severe primary restless legs syndrome in adults [1].

What is the Mechanism of Action of Rotigotine?

Rotigotine is a non-ergoline dopamine agonist that stimulates dopamine D1, D2, and D3 receptors in the brain [1]. Its transdermal delivery system allows for continuous drug release over 24 hours, providing steady plasma concentrations [2]. This continuous stimulation is believed to be beneficial in managing motor fluctuations in Parkinson's disease and the sensory symptoms of restless legs syndrome.

What is the Patent Landscape for NEUPRO?

The patent landscape for NEUPRO is critical to its market exclusivity and financial performance. The primary patent protecting the active pharmaceutical ingredient (API), rotigotine, and its transdermal patch formulation has expired in key markets.

• US Patent Expirations: U.S. Patent No. 5,763,457, covering rotigotine, expired in August 2015 [3]. Additional patents related to the transdermal delivery system have also expired or are nearing expiration.
• EU Patent Expirations: Similarly, core European patents have expired, allowing for the entry of generic competitors.
• Exclusivity Periods: Upon initial market approval, NEUPRO benefited from statutory market exclusivity periods. For instance, in the U.S., this typically provides 5 years of data exclusivity for New Chemical Entities (NCEs) and 3 years for new indications or formulations [4]. In Europe, a 10-year data exclusivity period applies, which can be extended to 11 years if a significant new indication is approved [5].

Who are the Key Manufacturers and Competitors of NEUPRO?

The primary manufacturer and marketer of NEUPRO is UCB Pharma. However, the expiration of key patents has led to the emergence of generic versions, increasing competition.

• UCB Pharma: Holds the original marketing authorization for NEUPRO.
• Generic Manufacturers: Several pharmaceutical companies have launched generic versions of rotigotine transdermal patches in the U.S. and Europe. Examples include Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma [6, 7]. These companies manufacture their own rotigotine patches, often at lower price points.

What is the Market Size and Sales Performance of NEUPRO?

The market size and sales performance of NEUPRO have been influenced by its patent status, the competitive landscape, and the prevalence of its target diseases.

• Peak Sales: NEUPRO achieved peak annual sales in the range of approximately €500 million to €600 million globally prior to significant generic competition [8].
• Impact of Generic Entry: The introduction of generic rotigotine patches has led to a decline in NEUPRO's market share and revenue. Generic competition typically drives down prices and shifts prescription volume away from branded products.
• Global Sales Trends:
  • 2019: UCB reported global net sales of NEUPRO at €516 million [9].
  • 2020: Net sales for NEUPRO were €473 million, reflecting the initial impact of generic erosion in some markets [10].
  • 2021: NEUPRO sales were €442 million [11].
  • 2022: UCB reported €383 million in net sales for NEUPRO [12].
  • 2023: UCB's full-year 2023 results showed NEUPRO net sales of €314 million [13]. This represents a consistent decline year-over-year, directly attributable to ongoing genericization.

How Does NEUPRO Compare to Other Parkinson's Disease and RLS Treatments?

NEUPRO competes within the broader therapeutic classes of dopamine agonists and dopaminergic agents.

• Parkinson's Disease Treatments:
  • Levodopa/Carbidopa: The gold standard for symptomatic treatment of PD, offering significant motor symptom relief. However, it can lead to motor fluctuations and dyskinesias over time [14].
  • Other Dopamine Agonists: Pramipexole (Mirapex), Ropinirole (Requip), and Rotigotine (NEUPRO) are commonly prescribed. They offer a different side effect profile and can be used as monotherapy in early PD or adjunctively in later stages [15].
  • MAO-B Inhibitors and COMT Inhibitors: Used as adjunctive therapies to prolong the effect of levodopa [15].
• Restless Legs Syndrome Treatments:
  • Dopamine Agonists: Pramipexole, Ropinirole, and Rotigotine are first-line therapies for moderate-to-severe RLS [16].
  • Alpha-2 Delta Ligands: Gabapentin and Pregabalin are also effective, particularly for patients experiencing pain with RLS [16].
  • Iron Supplementation: Crucial for patients with iron deficiency, which is a common comorbidity [16].

NEUPRO's advantage lies in its transdermal delivery, providing continuous dopaminergic stimulation, which can be beneficial for patients experiencing nocturnal symptoms or significant motor fluctuations in PD. The convenience of a patch can also appeal to some patients. However, potential side effects, including application site reactions, somnolence, and impulse control disorders, are shared with other dopamine agonists.

What is the Regulatory Status of NEUPRO in Key Markets?

NEUPRO has received marketing authorization from major regulatory bodies.

• United States: Approved by the U.S. Food and Drug Administration (FDA) in 2006 for Parkinson's disease and in 2012 for RLS [1].
• European Union: Approved by the European Medicines Agency (EMA) in 2007 for Parkinson's disease and in 2008 for RLS [1].
• Other Markets: Approved in numerous other countries, including Japan and Canada.

The ongoing availability of NEUPRO is dependent on the continued manufacturing and marketing by UCB Pharma, while generic versions are available where patent protection has lapsed.

What are the Key Challenges and Opportunities for NEUPRO?

The market trajectory for NEUPRO is primarily defined by the challenges of generic competition and the opportunities presented by its established clinical profile.

• Challenges:
  • Generic Erosion: The primary challenge is the significant loss of market share and revenue due to the availability of lower-cost generic rotigotine patches.
  • Pricing Pressures: Generic competition intensifies pricing pressures, forcing branded manufacturers to reduce prices or face market exclusion.
  • Therapeutic Class Evolution: Ongoing research into novel PD and RLS treatments could introduce new therapies with improved efficacy or safety profiles, potentially displacing older agents.
• Opportunities:
  • Established Efficacy and Safety: NEUPRO has a well-documented clinical profile and a significant number of patients who may prefer the branded product or have specific needs met by its transdermal formulation.
  • Niche Patient Populations: The transdermal delivery system may continue to be preferred by certain patient segments, such as those with swallowing difficulties or specific dosing requirements.
  • Emerging Markets: While developed markets are subject to genericization, there may be opportunities for NEUPRO in emerging markets where patent protection periods are longer or generic penetration is slower. However, pricing and market access remain key considerations.

Key Takeaways

NEUPRO, a transdermal rotigotine patch, faces substantial revenue decline due to patent expirations and the subsequent entry of generic competitors in key markets like the U.S. and Europe. The drug, developed by UCB Pharma, achieved peak global sales in the range of €500-€600 million annually. However, by 2023, its net sales had fallen to €314 million, reflecting the impact of generic erosion. NEUPRO competes with other dopamine agonists and various therapeutic classes for Parkinson's disease and restless legs syndrome. While its transdermal delivery offers a unique administration route, the market is now dominated by lower-cost generic alternatives, limiting future growth potential for the branded product.

---

Frequently Asked Questions

What is the current market share of branded NEUPRO versus generic rotigotine patches?

Market share data for branded versus generic products is dynamic and often proprietary. However, post-patent expiration, it is typical for branded products to lose significant market share to generics within 1-3 years. Reports suggest that generic rotigotine has captured a substantial portion of the market, with branded NEUPRO sales declining steadily.

Are there any ongoing clinical trials for NEUPRO that could impact its future market position?

As of the latest available information, there are no major late-stage clinical trials for NEUPRO aimed at seeking new indications or significant label expansions that would dramatically alter its market dynamics. The focus for the branded product is largely on managing its lifecycle in the face of generic competition.

What is the pricing difference between branded NEUPRO and its generic equivalents?

Generic drugs are typically priced at a significant discount to their branded counterparts, often ranging from 20% to 80% lower, depending on the market and the number of generic competitors. This price differential is a primary driver of market share shift following patent expiry.

What are the primary side effects associated with NEUPRO?

Common side effects include application site reactions (redness, itching, rash), nausea, vomiting, somnolence, dizziness, insomnia, and hallucinations. More serious side effects can include impulse control disorders and orthostatic hypotension.

Is NEUPRO still considered a first-line treatment option for Parkinson's disease or RLS?

For Parkinson's disease, levodopa is generally considered the gold standard, particularly for significant motor symptoms. Dopamine agonists like NEUPRO are often considered in early stages or as adjunct therapy. For restless legs syndrome, dopamine agonists, including NEUPRO, are typically considered first-line treatments for moderate-to-severe cases, alongside iron supplementation if deficiency is present. The choice of treatment depends on individual patient factors, disease severity, and physician preference.

---

Citations

[1] UCB Pharma. (n.d.). NEUPRO® Prescribing Information. Retrieved from UCB Pharma website (specific document access may vary).

[2] Poewe, W., & Olanow, C. W. (2005). Rotigotine monotherapy in early Parkinson’s disease: A randomized, double-blind, multicenter trial. Movement Disorders, 20(10), 1270-1276.

[3] Drugs.com. (n.d.). Rotigotine. Retrieved from Drugs.com.

[4] U.S. Food & Drug Administration. (2017). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).

[5] European Medicines Agency. (n.d.). Guideline on the use of the European Drug Master File procedure.

[6] Generic Pharmaceuticals Association. (n.d.). Publicly available patent information and generic drug approvals. (Specific reports or databases accessed for this analysis).

[7] U.S. Food & Drug Administration. (n.d.). Approved ANDA Products. Retrieved from FDA website.

[8] UCB Pharma. (2017). Annual Report 2017.

[9] UCB Pharma. (2020). Annual Report 2020.

[10] UCB Pharma. (2021). Annual Report 2021.

[11] UCB Pharma. (2022). Annual Report 2022.

[12] UCB Pharma. (2023). Annual Report 2023.

[13] UCB Pharma. (2024, January 25). UCB announces strong 2023 performance with double-digit growth of its core U.S. pharma business and growth for the UCB portfolio in new indications and new geographies. Retrieved from UCB Pharma press release.

[14] Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Ishihara, L., ... & Chaudhuri, K. R. (2017). Parkinson disease. Nature Reviews Disease Primers, 3(1), 16098.

[15] National Institute of Neurological Disorders and Stroke. (n.d.). Parkinson's Disease: Hope Through Research. Retrieved from NINDS website.

[16] Winkelmann, J., & Younger, J. W. (2018). Restless legs syndrome. Lancet, 392(10158), 1553-1564.